Last reviewed · How we verify

NCT03803176

Tissue Plasminogen Activator & Plasminogen Activator Inhibitor Type-1 In Gingival Tissues Of Chronic Periodontitis

Completed Last updated 14 January 2019
What this trial tests

trial testing Open Flap Debridement in Chronic Periodontitis in 30 participants. Completed in 14 August 2018.

Timeline
12 February 2018
Primary endpoint
11 June 2018
14 August 2018

Quick facts

Lead sponsorCairo University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment30
Start date12 February 2018
Primary completion11 June 2018
Estimated completion14 August 2018
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Cairo University

Who can join

Adults 30 to 50, any sex, with Chronic Periodontitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Tissue Plasminogen Activator and Plasminogen Activator Inhibitor Type-1 Gene Expression will be evaluated clinically and histopathologically through Hematoxylin and eosin as well as by quantitative reverse transcription polymerase chain reaction in the gingival tissues of chronic periodontitis in an attempt to investigate whether the expression of these proteins could be involved in the disease pathogenesis or not, and to assess as well if their expression will be affected by the applied surgical periodontal treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Open Flap Debridement

Trials testing the same drug.

Other recruiting trials for Chronic Periodontitis

Currently open trials in the same condition.

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03803176.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing